Sook Jung Jo

First-SIGNAL: First-Line Single-Agent Iressa Versus Gemcitabine and Cisplatin Trial in Never-Smokers With Adenocarcinoma of the Lung

Ji‐Youn Han, Keunchil Park, Sang‐We Kim et al. · Journal of Clinical Oncology · 2012 · 735 citations

Medicine, Oncology, Pharmacology +11

S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial

Yong Sang Hong, Young Suk Park, Ho Yeong Lim et al. · The Lancet Oncology · 2012 · 132 citations

Medicine, Oncology, Chemotherapy +9

Gefitinib versus pemetrexed as second‐line treatment in patients with nonsmall cell lung cancer previously treated with platinum‐based chemotherapy (KCSG‐LU08‐01)

Jong‐Mu Sun, Ki Hyeong Lee, Sang‐we Kim et al. · Cancer · 2012 · 92 citations · Full text

Medicine, Oncology, Pharmacotherapy +10

Whole blood Epstein-Barr virus DNA load as a diagnostic and prognostic surrogate: extranodal natural killer/T-cell lymphoma

Hyo Song Kim, Kyung‐Hee Kim, Kyoung Ha Kim et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2009 · 70 citations · Full text

Life Sciences, Immunology, Oncology +15

S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial

Seung Tae Kim, Yong Sang Hong, Ho Yeong Lim et al. · BMC Cancer · 2014 · 22 citations · Full text

Medicine, Oncology, Pharmacology +12